Last reviewed · How we verify

NCT06667037

Orthokeratology and 0.01% Atropine Sequential Treatment for Myopia Control

Recruiting now NA Last updated 26 February 2025
What this trial tests

NA trial testing Ortho-k lenses in Myopia in 194 participants. Currently enrolling.

Timeline
21 September 2024
Primary endpoint
31 December 2026
31 March 2027

Quick facts

Lead sponsorZhongshan Ophthalmic Center, Sun Yat-sen University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment194
Start date21 September 2024
Primary completion31 December 2026
Estimated completion31 March 2027
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University

Who can join

Adults 8 to 15, any sex, with Myopia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this multicenter randomized clinical trial is to evaluate the myopia control effect of orthokeratology and 0.01% atropine sequential treatment in children and adolescents, as compared to continuous treatment with orthokeratology.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Ortho-k lenses

Trials testing the same drug.

Other recruiting trials for Myopia

Currently open trials in the same condition.

Other Zhongshan Ophthalmic Center, Sun Yat-sen University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06667037.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing